Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy

Ítems similars

• Reply to ‘Comment on ‘Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''
  per: Fujii, Takeo, et al.
  Publicat: (2017)
• Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2‐Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab
  per: Kogawa, Takahiro, et al.
  Publicat: (2020)
• High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer
  per: Kogawa, Takahiro, et al.
  Publicat: (2016)
• The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer.
  per: Chainitikun, Sudpreeda, et al.
  Publicat: (2020)
• Long‐Term Survival of De Novo Stage IV Human Epidermal Growth Receptor 2 (HER2) Positive Breast Cancers Treated with HER2‐Targeted Therapy
  per: Wong, Yao, et al.
  Publicat: (2018)